DNAPrint Genomics Key Fundamental Indicators
DNAPrint Genomics technical analysis allows you to utilize past data patterns in order to determine a pattern that computes the direction of the firm's future prices.
DNAPrint Genomics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.9228 | Revenue |
DNAPrint | Select Account or Indicator | Build AI portfolio with DNAPrint Stock |
DNAPrint Genomics Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DNAPrint Genomics Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DNAPrint Genomics Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DNAPrint Genomics Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DNAPrint Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for DNAPrint Genomics is extremely important. It helps to project a fair market value of DNAPrint Stock properly, considering its historical fundamentals such as Current Valuation. Since DNAPrint Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DNAPrint Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DNAPrint Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
DNAPrint Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to DNAPrint Genomics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of DNAPrint Genomics.
| 11/23/2025 |
| 02/21/2026 |
If you would invest 0.00 in DNAPrint Genomics on November 23, 2025 and sell it all today you would earn a total of 0.00 from holding DNAPrint Genomics or generate 0.0% return on investment in DNAPrint Genomics over 90 days. DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services More
DNAPrint Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure DNAPrint Genomics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess DNAPrint Genomics upside and downside potential and time the market with a certain degree of confidence.
DNAPrint Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for DNAPrint Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as DNAPrint Genomics' standard deviation. In reality, there are many statistical measures that can use DNAPrint Genomics historical prices to predict the future DNAPrint Genomics' volatility.DNAPrint Genomics Backtested Returns
We have found zero technical indicators for DNAPrint Genomics, which you can use to evaluate the volatility of the firm. The firm owns a Beta (Systematic Risk) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and DNAPrint Genomics are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
DNAPrint Genomics has no correlation between past and present. Overlapping area represents the amount of predictability between DNAPrint Genomics time series from 23rd of November 2025 to 7th of January 2026 and 7th of January 2026 to 21st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of DNAPrint Genomics price movement. The serial correlation of 0.0 indicates that just 0.0% of current DNAPrint Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, DNAPrint Genomics has a Current Valuation of 5.64 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is notably lower than that of the firm.
DNAPrint Genomics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DNAPrint Genomics's current stock value. Our valuation model uses many indicators to compare DNAPrint Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DNAPrint Genomics competition to find correlations between indicators driving DNAPrint Genomics's intrinsic value. More Info.DNAPrint Genomics is rated # 2 in return on asset category among its peers. It is one of the top stocks in profit margin category among its peers . At this time, DNAPrint Genomics' Net Loss is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value DNAPrint Genomics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.DNAPrint Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.DNAPrint Genomics is currently under evaluation in current valuation category among its peers.
DNAPrint Fundamentals
| Return On Asset | -1.05 | ||||
| Profit Margin | (2.36) % | ||||
| Operating Margin | (7.31) % | ||||
| Current Valuation | 5.64 M | ||||
| Shares Owned By Institutions | 0.18 % | ||||
| Price To Sales | 0.20 X | ||||
| Revenue | 2.43 M | ||||
| Gross Profit | 446.37 K | ||||
| EBITDA | (5.78 M) | ||||
| Net Income | (12.35 M) | ||||
| Cash And Equivalents | 134.35 K | ||||
| Total Debt | 240 K | ||||
| Current Ratio | 0.17 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (5.78 M) | ||||
| Number Of Employees | 24 | ||||
| Beta | 86.78 | ||||
| Market Capitalization | 386.76 K | ||||
| Total Asset | 10.27 M | ||||
| Retained Earnings | (45.53 M) | ||||
| Working Capital | (9.35 M) | ||||
| Current Asset | 1.89 M | ||||
| Current Liabilities | 11.24 M | ||||
| Net Asset | 10.27 M |
About DNAPrint Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DNAPrint Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNAPrint Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNAPrint Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 2.8 M | 2.9 M | |
| Cost Of Revenue | 1.5 M | 983.6 K | |
| Research And Ddevelopement To Revenue | 3.04 | 2.89 | |
| Capex To Revenue | 0.19 | 0.18 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (4.19) | (3.98) |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.